Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy.

Journal of endocrinological investigation·2021
Same author

Consequences of atmospheric contamination by radioiodine: the Chernobyl and Fukushima accidents.

Endocrine·2020
Same author

Locally unresectable differentiated thyroid cancer: outcomes and perspectives.

Endocrine·2020
Same author

Corrigendum to "Thermal-ablation of vertebral metastases prevents adverse events in patients with differentiated thyroid carcinoma" [Eur. J. Radiol. 119 (2019) 108650].

European journal of radiology·2019
Same author

Thermal-ablation of vertebral metastases prevents adverse events in patients with differentiated thyroid carcinoma.

European journal of radiology·2019
Same author

Static patella tilt and axial engagement in knee extension are mainly influenced by knee torsion, the tibial tubercle-trochlear groove distance (TTTG), and trochlear dysplasia but not by femoral or tibial torsion.

Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA·2019

Related Experiment Video

Updated: Jun 2, 2026

"Sun's Seven-Step Technique" for Endoscopic En-Bloc Resection of Thyroid Cancer via the Chest-Breast Approach
07:45

"Sun's Seven-Step Technique" for Endoscopic En-Bloc Resection of Thyroid Cancer via the Chest-Breast Approach

Published on: November 28, 2025

[Management of refractory thyroid cancers].

M Schlumberger1

  • 1Service de Médecine Nucléaire et d'oncologie endocrinienne, Université Paris-Sud et Institut Gustave-Roussy, Villejuif cedex, France. schlumbg@igr.fr

Annales D'Endocrinologie
|April 26, 2011
PubMed
Summary

Novel kinase inhibitors targeting VEGF and MAPkinase pathways show efficacy in refractory thyroid cancers. These targeted therapies provide partial responses or long-term stabilization in over half of patients with differentiated and medullary thyroid cancers.

More Related Videos

Mixed Reality Assisted Radical Endoscopic Thyroidectomy
08:06

Mixed Reality Assisted Radical Endoscopic Thyroidectomy

Published on: January 31, 2025

Related Experiment Videos

Last Updated: Jun 2, 2026

"Sun's Seven-Step Technique" for Endoscopic En-Bloc Resection of Thyroid Cancer via the Chest-Breast Approach
07:45

"Sun's Seven-Step Technique" for Endoscopic En-Bloc Resection of Thyroid Cancer via the Chest-Breast Approach

Published on: November 28, 2025

Mixed Reality Assisted Radical Endoscopic Thyroidectomy
08:06

Mixed Reality Assisted Radical Endoscopic Thyroidectomy

Published on: January 31, 2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Significant advancements in understanding thyroid cancer molecular biology over the past two decades.
  • Development of novel therapeutic strategies for refractory thyroid cancer cases.

Purpose of the Study:

  • To evaluate the efficacy of kinase inhibitors in treating differentiated and medullary thyroid cancers.
  • To assess the impact of these inhibitors on angiogenesis and the MAPkinase pathway.

Main Methods:

  • Utilizing kinase inhibitors that target Vascular Endothelial Growth Factor (VEGF) receptors.
  • Investigating agents that also inhibit the Mitogen-Activated Protein kinase (MAPK) pathway.

Main Results:

  • Kinase inhibitors demonstrated effectiveness in differentiated and medullary thyroid cancers.
  • Over half of the patients experienced partial response or long-term disease stabilization.

Conclusions:

  • Kinase inhibitors represent a promising therapeutic option for refractory thyroid cancers.
  • Targeting VEGF and MAPkinase pathways can lead to significant clinical benefits in thyroid cancer patients.